The DOI matches its Crossref record; 110 of the 114 references it cites were found in a registry or an index.
Epigenetic regulation of somatostatin and somatostatin receptors in neuroendocrine tumors and other types of cancer.
Open accessAbstract
Both somatostatin (SST) and somatostatin receptors (SSTRs) are proteins with important functions in both physiological tissue and in tumors, particularly in neuroendocrine tumors (NETs). NETs are frequently characterized by high SSTRs expression levels. SST analogues (SSAs) that bind and activate SSTR have anti-proliferative and anti-secretory activity, thereby reducing both the growth as well as the hormonal symptoms of NETs. Moreover, the high expression levels of SSTR type-2 (SSTR2) in NETs is a powerful target for therapy with radiolabeled SSAs. Due to the important role of both SST and SSTRs, it is of great importance to elucidate the mechanisms involved in regulating their expression in NETs, as well as in other types of tumors. The field of epigenetics recently gained interest in NET research, highlighting the importance of this process in regulating the expression of gene and protein expression. In this review we will discuss the role of the epigenetic machinery in controlling the expression of both SSTRs and the neuropeptide SST. Particular attention will be given to the epigenetic regulation of these proteins in NETs, whereas the involvement of the epigenetic machinery in other types of cancer will be discussed as well. In addition, we will discuss the possibility to target enzymes involved in the epigenetic machinery to modify the expression of the SST-system, thereby possibly improving therapeutic options.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
Most PRRTs using radiolabeled SSAs and antagonists have until now depended substantially on the most prominently expressed SSTR2.
“Most PRRTs using radiolabeled SSAs and antagonists has until now depended substantially on the most prominently expressed SSTR2 (142).”
From Alpha-peptide receptor radionuclide therapy using actinium-225 labeled somatostatin receptor agonists and antagonists (2022) · cites this paper as [142]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
DNA methylation and its basic function
Moore, L. D., Le, T., & Fan, G. (2013) · Neuropsychopharmacology · doi:10.1038/npp.2012.112 · Cited by 4,906
Phase 3 Trial of 177 Lu-Dotatate for Midgut Neuroendocrine Tumors
Strosberg, J., El-Haddad, G., Wolin, E., Hendifar, A., Yao, J., Chasen, B., Mittra, E., Kunz, P. L., Kulke, M. H., Jacene, H., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1607427 · Cited by 3,308
Sharma, S., Kelly, T. K., & Jones, P. A. (2010) · Carcinogenesis · doi:10.1093/carcin/bgp220 · Cited by 2,637
Rinke, A., Müller, H., Schade‐Brittinger, C., Klose, K., Barth, P. J., Wied, M., Mayer, C., Aminossadati, B., Pape, U., Bläker, M., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2009.22.8510 · Cited by 2,507
Erasers of Histone Acetylation: The Histone Deacetylase EnzymesPreprint
Seto, E., & Yoshida, M. (2014) · Cold Spring Harbor Perspectives in Biology · doi:10.1101/cshperspect.a018713 · Cited by 2,094
Lanreotide in Metastatic Enteropancreatic Neuroendocrine Tumors
Caplin, M. E., Pavel, M. E., Ćwikła, J. B., Phan, A. T., Raderer, M., Sedláčková, E., Cadiot, G., Wolin, E. M., Capdevila, J., Wall, L. R., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1316158 · Cited by 1,937
Somatostatin and Its Receptor Family
Patel, Y. (1999) · Frontiers in Neuroendocrinology · doi:10.1006/frne.1999.0183 · Cited by 1,648
Kwekkeboom, D. J., de Herder, W. W., Kam, B. L. R., van Eijck, C. H. J., van Essen, M., Kooij, P. P. M., Feelders, R. A., van Aken, M. O., & Krenning, E. P. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.15.2553 · Cited by 1,454
Kwekkeboom, D. J., Teunissen, J. J., Bakker, W. H., Kooij, P. P., de Herder, W. W., Feelders, R. A., van Eijck, C. H., Esser, J.-P., Kam, B. L., & Krenning, E. P. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.08.066 · Cited by 657
Brabander, T., van der Zwan, W. A., Teunissen, J. J. M., Kam, B. L. R., Feelders, R. A., de Herder, W. W., van Eijck, C. H. J., Franssen, G. J. H., Krenning, E. P., & Kwekkeboom, D. J. (2017) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-16-2743 · Cited by 616
Epigenetic modifications in cancer
Kanwal, R., & Gupta, S. (2011) · Clinical Genetics · doi:10.1111/j.1399-0004.2011.01809.x · Cited by 551
Epigenetics and human disease: translating basic biology into clinical applications
Rodenhiser, D. I. (2006) · Canadian Medical Association Journal · doi:10.1503/cmaj.050774 · Cited by 478
Papotti, M. G., Bongiovanni, M., Volante, M., Allìa, E., Landolfi, S., Helboe, L., Schindler, M., Cole, S., & Bussolati, G. (2002) · Archiv für Pathologische Anatomie und Physiologie und für Klinische Medicin · doi:10.1007/s00428-002-0609-x · Cited by 335
Regulation and function of somatostatin receptors
Olias, G., Viollet, C., Kusserow, H., Epelbaum, J., & Meyerhof, W. (2004) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2004.02402.x · Cited by 322
Günther, T., Tulipano, G., Dournaud, P., Bousquet, C., Csaba, Z., Kreienkamp, H., Lupp, A., Korbonits, M., Castano, J. P., Wester, H., et al. (2018) · Pharmacological Reviews · doi:10.1124/pr.117.015388 · Cited by 264
Specific or not specific recruitment of DNMTs for DNA methylation, an epigenetic dilemma
Hervouet, É., Peixoto, P., Delage-Mourroux, R., Boyer‐Guittaut, M., & Cartron, P. (2018) · Clinical Epigenetics · doi:10.1186/s13148-018-0450-y · Cited by 255
Histone modifications and their role in epigenetics of atopy and allergic diseases
Alhamwe, B. A., Khalaila, R., Wolf, J., von Bülow, V., Harb, H., Alhamdan, F., Hii, C. S. T., Prescott, S. L., Ferrante, A., Renz, H., et al. (2018) · Allergy Asthma and Clinical Immunology · doi:10.1186/s13223-018-0259-4 · Cited by 248
van Essen, M., Krenning, E. P., de Jong, M., Valkema, R., & Kwekkeboom, D. J. (2007) · Acta Oncologica · doi:10.1080/02841860701441848 · Cited by 223
Genetics and Epigenetics of Gastroenteropancreatic Neuroendocrine Neoplasms
Mafficini, A., & Scarpa, A. (2019) · Endocrine Reviews · doi:10.1210/er.2018-00160 · Cited by 221
Somatostatin Analogues in the Treatment of Neuroendocrine Tumors: Past, Present and Future
Stueven, A. K., Kayser, A., Wetz, C., Amthauer, H., Wree, A., Tacke, F., Wiedenmann, B. J., Roderburg, C., & Jann, H. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20123049 · Cited by 219
Role of epigenetics in developmental biology and transgenerational inheritance
Skinner, M. K. (2011) · Birth Defects Research Part C Embryo Today Reviews · doi:10.1002/bdrc.20199 · Cited by 217
Advances in the Diagnosis and Management of Well-Differentiated Neuroendocrine Neoplasms
Hofland, J., Kaltsas, G., & de Herder, W. W. (2019) · Endocrine Reviews · doi:10.1210/endrev/bnz004 · Cited by 211
Alvarez, M. J., Subramaniam, P. S., Tang, L. H., Grunn, A., Aburi, M., Rieckhof, G., Komissarova, E. V., Hagan, E. A., Bodei, L., Clemons, P. A., et al. (2018) · Nature Genetics · doi:10.1038/s41588-018-0138-4 · Cited by 210
Marek, L., Hamacher, A., Hansen, F. K., Kuna, K., Gohlke, H., Kassack, M. U., & Kurz, T. (2012) · Journal of Medicinal Chemistry · doi:10.1021/jm301254q · Cited by 185
Mori, Y., Cai, K., Cheng, Y., Wang, S., Paun, B. C., Hamilton, J. P., Jin, Z., Sato, F., Berki, A. T., Kan, T., et al. (2006) · Gastroenterology · doi:10.1053/j.gastro.2006.06.006 · Cited by 185
Antitumor effects of somatostatin
Pyronnet, S., Bousquet, C., Najib, S., Azar, R., Laklai, H., & Susini, C. (2008) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2008.02.002 · Cited by 176
Somatostatin and Somatostatin Receptor Physiology
Barnett, P. S. (2003) · Endocrine · doi:10.1385/endo:20:3:255 · Cited by 175
Righi, L., Volante, M., Tavaglione, V., Billè, A., Daniele, L., Angusti, T., Inzani, F. S., Pelosi, G., Rindi, G., & Papotti, M. G. (2009) · Annals of Oncology · doi:10.1093/annonc/mdp334 · Cited by 173
Singh, S., Granberg, D. O., Wolin, E. M., Warner, R. R. P., Sissons, M., Kolarova, T. R., Goldstein, G., Pavel, M. E., Öberg, K., & Leyden, J. (2016) · Journal of Global Oncology · doi:10.1200/jgo.2015.002980 · Cited by 159
Zhao, J., Liang, Q., Cheung, K., Kang, W., Lung, R. W. M., TONG, J. H. M., To, K. F., Sung, J. J. �., & Yu, J. Q. (2012) · Cancer · doi:10.1002/cncr.27724 · Cited by 150
Genetic and epigenetic drivers of neuroendocrine tumours (NET)
Domenico, A. D., Wiedmer, T., Marinoni, I., & Perren, A. A. (2017) · Endocrine Related Cancer · doi:10.1530/erc-17-0012 · Cited by 145
Epigenetic treatment of pancreatic cancer: is there a therapeutic perspective on the horizon?
Heßmann, E., Johnsen, S. A., Siveke, J. T., & Ellenrieder, V. (2016) · Gut · doi:10.1136/gutjnl-2016-312539 · Cited by 139
van Vliet, E. I., van Eijck, C. H. J., de Krijger, R. R., van Dijkum, E. J. M. N., Teunissen, J. J. M., Kam, B. L. R., de Herder, W. W., Feelders, R. A., Bonsing, B. A., Brabander, T., et al. (2015) · Journal of Nuclear Medicine · doi:10.2967/jnumed.115.158899 · Cited by 126
Appetecchia, M., & Baldelli, R. (2010) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/1756-9966-29-19 · Cited by 125
MiR-185 Targets the DNA Methyltransferases 1 and Regulates Global DNA Methylation in human glioma
Zhang, Z., Tang, H., Wang, Z., Zhang, B., Liu, W., Hong-mei, L., Xiao, L., Liu, X., Wang, R., Li, X., et al. (2011) · Molecular Cancer · doi:10.1186/1476-4598-10-124 · Cited by 122
Peptide Receptor Targeting in Cancer: The Somatostatin Paradigm
Barbieri, F., Bajetto, A., Pattarozzi, A., Gatti, M., Würth, R., Thellung, S., Corsaro, A., Villa, V., Nizzari, M., & Florio, T. (2013) · International Journal of Peptides · doi:10.1155/2013/926295 · Cited by 121
Wang, C., Henkes, L. M., Doughty, L. B., He, M., Wang, D., Meyer‐Almes, F., & Cheng, Y. (2011) · Journal of Natural Products · doi:10.1021/np200324x · Cited by 120
Association Between Somatostatin Receptor Expression and Clinical Outcomes in Neuroendocrine Tumors
Qian, Z. R., Li, T., Ter‐Minassian, M., Yang, J., Chan, J. A.-W., Brais, L. K., Masugi, Y., Thiaglingam, A., Brooks, N. V., Nishihara, R., et al. (2016) · Pancreas · doi:10.1097/mpa.0000000000000700 · Cited by 114
HS-1371, a novel kinase inhibitor of RIP3-mediated necroptosis
Park, H.-H., Park, S.-Y., Mah, S., Park, J.-H., Hong, S.-S., Hong, S., & Kim, Y.-S. (2018) · Experimental & Molecular Medicine · doi:10.1038/s12276-018-0152-8 · Cited by 110
Gailhouste, L., Liew, L. C., Hatada, I., Nakagama, H., & Ochiya, T. (2018) · Cell Death and Disease · doi:10.1038/s41419-018-0487-z · Cited by 97
Mizutani, G., Nakanishi, Y., Watanabe, N., Honma, T., Obana, Y., Seki, T., Ohni, S., & Nemoto, N. (2012) · ACTA HISTOCHEMICA ET CYTOCHEMICA · doi:10.1267/ahc.12006 · Cited by 95
The Evolution of Neuroendocrine Tumor Treatment Reflected by ENETS Guidelines
Zandee, W. T., & de Herder, W. W. (2018) · Neuroendocrinology · doi:10.1159/000486096 · Cited by 88
The neuroendocrine phenotype, genomic profile and therapeutic sensitivity of GEPNET cell lines
Hofving, T., Arvidsson, Y., Almobarak, B., Inge, L., Pfragner, R., Persson, M., Stenman, G., Kristiansson, E., Johanson, V., & Nilsson, O. (2018) · Endocrine Related Cancer · doi:10.1530/erc-17-0445 · Cited by 86
Yang, S. (2009) · International Journal of Oncology · doi:10.3892/ijo_00000513 · Cited by 76
Peptide receptor radionuclide therapy (PRRT) for GEP-NETs
Bergsma, H., van Vliet, E. I., Teunissen, J. J. M., Kam, B. L. R., de Herder, W. W., Peeters, R. P., Krenning, E. P., & Kwekkeboom, D. J. (2012) · Best Practice & Research Clinical Gastroenterology · doi:10.1016/j.bpg.2013.01.004 · Cited by 75
Aberrantly methylated-differentially expressed genes and pathways in colorectal cancer
Liu, J., Li, H. R., Sun, L. L., Wang, Z., Xing, C., & Yuan, Y. (2017) · Cancer Cell International · doi:10.1186/s12935-017-0444-4 · Cited by 75
Upregulation of Key Molecules for Targeted Imaging and Therapy
Taelman, V. F., Radojewski, P., Marincek, N., Ben-Shlomo, A., Grotzky, A., Olariu, C. I., Perren, A. A., Stettler, C., Krause, T., Meier, L. P., et al. (2016) · Journal of Nuclear Medicine · doi:10.2967/jnumed.115.165092 · Cited by 72
Pscherer, A., Dörflinger, U., Kirfel, J., Gawlas, K., Rüschoff, J., Buettner, R., & Schüle, R. (1996) · The EMBO Journal · doi:10.1002/j.1460-2075.1996.tb01058.x · Cited by 71
Jeffries, M. A., & Sawalha, A. H. (2014) · Expert Review of Clinical Immunology · doi:10.1586/1744666x.2015.994507 · Cited by 68
Morris, M. R., Gentle, D., Abdulrahman, M., Clarke, N. W., Brown, M. D., Kishida, T., Yao, M., Teh, B. T., Latif, F., & Maher, E. R. (2008) · British Journal of Cancer · doi:10.1038/sj.bjc.6604180 · Cited by 67
Veenstra, M. J., van Koetsveld, P. M., Dogan, F., Farrell, W. E., Feelders, R. A., Lamberts, S. W. J., de Herder, W. W., Vitale, G., & Hofland, L. J. (2016) · Oncotarget · doi:10.18632/oncotarget.9462 · Cited by 66
Is Glioblastoma an Epigenetic Malignancy?
Maleszewska, M., & Kaminska, B. (2013) · Cancers · doi:10.3390/cancers5031120 · Cited by 63
Klieser, E., Urbas, R., Stättner, S., Primavesi, F., Jäger, T., Dinnewitzer, A., Mayr, C., Kiesslich, T., Holzmann, K., Fazio, P. D., et al. (2017) · Human Pathology · doi:10.1016/j.humpath.2017.02.009 · Cited by 59
Torrisani, J., Hanoun, N., Laurell, H., Lopez, F., Maoret, J.-J., Souque, A., Susini, C., Cordelier, P., & Buscail, L. (2008) · Endocrinology · doi:10.1210/en.2007-1525 · Cited by 58
Ricketts, C. J., Morris, M. R., Gentle, D., Brown, M. D., Wake, N. C., Woodward, E. R., Clarke, N. W., Latif, F., & Maher, E. R. (2012) · Epigenetics · doi:10.4161/epi.7.3.19103 · Cited by 58
Jin, Z., Mori, Y., Hamilton, J. P., Olaru, A., Sato, F., Yang, J. P., Ito, T., Kan, T., Agarwal, R., & Meltzer, S. J. (2007) · Cancer · doi:10.1002/cncr.23135 · Cited by 57
Jaskula‐Sztul, R., Xu, W., Chen, G., Harrison, A. D., Dammalapati, A., Nair, R., Cheng, Y., Gong, S., & Chen, H. (2016) · Biomaterials · doi:10.1016/j.biomaterials.2016.03.010 · Cited by 57
Wang, B., Zhao, L., Chi, W., Cao, H., Cui, W., & Meng, W. (2019) · Epigenetics & Chromatin · doi:10.1186/s13072-019-0283-8 · Cited by 55
Sin, T. K., Mokhtar, N. M., Hassan, N. Z. A., Sagap, I., Rose, I. M., Harun, R., & Jamal, R. A. (2015) · Oncology Reports · doi:10.3892/or.2015.3993 · Cited by 53
Pharmacological Inhibition of Class IIA HDACs by LMK-235 in Pancreatic Neuroendocrine Tumor Cells
Wanek, J., Gaisberger, M., Beyreis, M., Mayr, C., Helm, K., Primavesi, F., Jäger, T., Fazio, P. D., Jakab, M., Wagner, A., et al. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms19103128 · Cited by 53
Misawa, K., Mochizuki, D., Imai, A., Endo, S., Mima, M., Misawa, Y., Kanazawa, T., Carey, T. E., & Mineta, H. (2016) · Oncotarget · doi:10.18632/oncotarget.8317 · Cited by 52
Jin, X., Auernhammer, C. J., Ilhan, H., Lindner, S., Nölting, S., Maurer, J., Spöttl, G., & Orth, M. (2019) · Journal of Nuclear Medicine · doi:10.2967/jnumed.118.224048 · Cited by 50
Patai, Á. V., Valcz, G., Hollósi, P., Kalmár, A., Péterfia, B., Patai, Á., Wichmann, B., Spisák, S., Barták, B. K., Leiszter, K., et al. (2015) · PLoS ONE · doi:10.1371/journal.pone.0133836 · Cited by 49
Sun, L., Qian, Q., Sun, G., Mackey, L. V., Fuselier, J. A., Coy, D. H., & Yu, C. (2015) · Journal of drug targeting · doi:10.3109/1061186x.2015.1066794 · Cited by 48
Chen, G., Jaskula‐Sztul, R., Harrison, A. D., Dammalapati, A., Xu, W., Cheng, Y., Chen, H., & Gong, S. (2016) · Biomaterials · doi:10.1016/j.biomaterials.2016.04.029 · Cited by 48
van der Zee, R. P., Richel, O., van Noesel, C. J. M., Novianti, P. W., Ciocănea‐Teodorescu, I., van Splunter, A. P., Duin, S., van den Berk, G. E. L., Meijer, C. J. L. M., Quint, W. G. V., et al. (2018) · Clinical Infectious Diseases · doi:10.1093/cid/ciy601 · Cited by 45
Gatto, F., Barbieri, F., Arvigo, M., Thellung, S., Amarù, J., Albertelli, M., Ferone, D., & Florio, T. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20163940 · Cited by 45
Ruszniewski, P. B., Valle, J. W., Lombard‐Bohas, C., Cuthbertson, D. J., Perros, P., Holubec, L., Fave, G. D., Smith, D. M., Niccoli, P., Maisonobe, P., et al. (2016) · Digestive and Liver Disease · doi:10.1016/j.dld.2015.12.013 · Cited by 44
Guenter, R. E., Aweda, T. A., Matos, D. M. C., Jang, S., Whitt, J. D., Cheng, Y., Liu, M., Chen, H., Lapi, S. E., & Jaskula‐Sztul, R. (2019) · Surgery · doi:10.1016/j.surg.2019.05.092 · Cited by 44
Qiu, C. (2006) · World Journal of Gastroenterology · doi:10.3748/wjg.v12.i13.2011 · Cited by 41
Sun, G., Mackey, L. V., Coy, D. H., Yu, C., & Sun, L. (2015) · Journal of Cancer · doi:10.7150/jca.12135 · Cited by 41
Analysis of somatostatin receptor subtype mRNA expression in human breast cancer
Evans, A., Crook, T., Laws, S., Gough, A. C., Royle, G. T., & Primrose, J. M. (1997) · British Journal of Cancer · doi:10.1038/bjc.1997.143 · Cited by 39
Franko-Tobin, L. G., Mackey, L. V., Huang, W. Y., Song, X., Jin, B., Luo, J., Morris, L. M., Liu, M., Fuselier, J. A., Coy, D. H., et al. (2012) · The Oncologist · doi:10.1634/theoncologist.2011-0269 · Cited by 39
Discovery of DNA methylation markers in cervical cancer using relaxation ranking
Ongenaert, M., Wisman, G. B. A., Volders, H. H., Koning, A. J., van der Zee, A. G. J., Criekinge, W. V., & Schuuring, E. M. D. (2008) · BMC Medical Genomics · doi:10.1186/1755-8794-1-57 · Cited by 38
The Somatostatin Analogue Octreotide Inhibits Growth of Small Intestine Neuroendocrine Tumour Cells
Li, S., Martijn, C., Cui, T., Essaghir, A., Luque, R. M., Demoulin, J., Castano, J. P., Öberg, K., & Giandomenico, V. (2012) · PLoS ONE · doi:10.1371/journal.pone.0048411 · Cited by 38
Zhao, J., Liang, Q., Cheung, K.-F., Kang, W., Dong, Y., Lung, R. W. M., TONG, J. H. M., To, K., Sung, J. J. �., & Yu, J. Q. (2013) · British Journal of Cancer · doi:10.1038/bjc.2013.263 · Cited by 38
Tsai, C., Leslie, J. S., Franko-Tobin, L. G., Prasnal, M. C., Yang, T., Mackey, L. V., Fuselier, J. A., Coy, D. H., Liu, M., Yu, C., et al. (2013) · Archives of Gynecology and Obstetrics · doi:10.1007/s00404-013-2762-7 · Cited by 37
Epigenetic Silencing of Somatostatin in Gastric Cancer
Jackson, K., Soutto, M., Peng, D., Hu, T., Marshal, D., & El-Rifai, W. M. (2010) · Digestive Diseases and Sciences · doi:10.1007/s10620-010-1422-z · Cited by 37
Cytotoxic Effects of Valproic Acid on Neuroendocrine Tumour Cells
Arvidsson, Y., Johanson, V., Pfragner, R., Wängberg, B., & Nilsson, O. (2015) · Neuroendocrinology · doi:10.1159/000441849 · Cited by 36
Xu, Y. F., Berelowitz, M., & Bruno, J. F. (1998) · Molecular and Cellular Endocrinology · doi:10.1016/s0303-7207(98)00072-0 · Cited by 36
Genomic structure and transcriptional regulation of the human somatostatin receptor type 2
Petersenn, S., Rasch, A. C., Presch, S., Beil, F. U., & Schulte, H. M. (1999) · Molecular and Cellular Endocrinology · doi:10.1016/s0303-7207(99)00161-6 · Cited by 36
Li, H., Liu, J., Liu, S., Yuan, Y., & Sun, L. L. (2017) · Digestive Diseases and Sciences · doi:10.1007/s10620-017-4740-6 · Cited by 36
Misawa, K., Misawa, Y., Kondo, H., Mochizuki, D., Imai, A., Fukushima, H., Uehara, T., Kanazawa, T., & Mineta, H. (2015) · PLoS ONE · doi:10.1371/journal.pone.0118588 · Cited by 33
Estrogen modulates serotonin effects on vasoconstriction through Src inhibition
Kim, J. G., Leem, Y.-E., Kwon, I., Kang, J., Bae, Y. M., & Cho, H. (2018) · Experimental & Molecular Medicine · doi:10.1038/s12276-018-0193-z · Cited by 32
Leiszter, K., Sípos, F., Galamb, O., Krenács, T., Veres, G., Wichmann, B., Fűri, I., Kalmár, A., Patai, Á. V., Tóth, K., et al. (2015) · PLoS ONE · doi:10.1371/journal.pone.0118332 · Cited by 30
Zou, Y., Tan, H., Zhao, Y., Zhou, Y., & Cao, L. (2018) · Oncology Letters · doi:10.3892/ol.2018.9773 · Cited by 30
Sun, L., He, Q., Tsai, C., Lei, J., Chen, J., Makcey, L. V., & Coy, D. H. (2018) · PubMed Central · Cited by 30
Diakatou, E., Kaltsas, G., Tzivras, M., Kanakis, G., Papaliodi, E., & Kontogeorgos, G. (2011) · Endocrine Pathology · doi:10.1007/s12022-011-9149-8 · Cited by 29
Kim, H., Kang, T.-W., Haam, K., Kim, S., Kim, S., Kim, S., Lee, S.-I., Song, K., Jeong, H. Y., & Kim, S. (2018) · Experimental & Molecular Medicine · doi:10.1038/s12276-018-0179-x · Cited by 28
Liu, Z., Márquez, M., Nilsson, S. F., & Holmberg, A. (2008) · Oncology Reports · doi:10.3892/or.20.1.151 · Cited by 26
Pulmonary Carcinoid Surface Receptor Modulation Using Histone Deacetylase Inhibitors
Guenter, R. E., Aweda, T. A., Matos, D. M. C., Whitt, J. D., Chang, A. W., Cheng, E. Y., Liu, M., Chen, H., Lapi, S. E., & Jaskula‐Sztul, R. (2019) · Cancers · doi:10.3390/cancers11060767 · Cited by 26
Shen, Z., Chen, X., Li, Q., Zhou, C., Li, J., Ye, H., & Duan, S. (2016) · Diagnostic Pathology · doi:10.1186/s13000-016-0461-y · Cited by 25
Development and Disease in a Dish: The Epigenetics of Neurodevelopmental Disorders
Lewis, E. M. A., & Kroll, K. L. (2018) · Epigenomics · doi:10.2217/epi-2017-0113 · Cited by 25
Hennigs, J. K., Müller, J., Adam, M., Spin, J. M., Riedel, E., Graefen, M., Bokemeyer, C., Sauter, G., Huland, H., Schlomm, T., et al. (2014) · PLoS ONE · doi:10.1371/journal.pone.0100469 · Cited by 24
Jang, S., Yu, X.-M., Odorico, S. K., Clark, M., Jaskula‐Sztul, R., Schienebeck, C. M., Kupcho, K. R., Harrison, A. D., Winston‐McPherson, G. N., Tang, W., et al. (2015) · Cancer Gene Therapy · doi:10.1038/cgt.2015.37 · Cited by 24
AB3-loaded and tumor-targeted unimolecular micelles for medullary thyroid cancer treatment
Jaskula‐Sztul, R., Chen, G., Dammalapati, A., Harrison, A. D., Tang, W., Gong, S., & Chen, H. (2016) · Journal of Materials Chemistry B · doi:10.1039/c6tb02530g · Cited by 24
Misawa, K., Mima, M., Imai, A., Mochizuki, D., Misawa, Y., Endo, S., Ishikawa, R., Kanazawa, T., & Mineta, H. (2018) · Clinical Epigenetics · doi:10.1186/s13148-018-0485-0 · Cited by 22
Epigenetics of gastroenteropancreatic neuroendocrine tumors: A clinicopathologic perspective
Finnerty, B. M., Gray, K., Moore, M. D., Zarnegar, R., & Fahey, T. J. (2017) · World Journal of Gastrointestinal Oncology · doi:10.4251/wjgo.v9.i9.341 · Cited by 20
Habeeb, N. M. A. W.-A., Ho, L., Olkhov‐Mitsel, E., Kron, K. J., Pethe, V., Lehman, M., Jovanović, L., Fleshner, N., van der Kwast, T., Nelson, C., et al. (2014) · OncoTarget · doi:10.18632/oncotarget.2313 · Cited by 19
Habeeb, N. W.-A., Ho, L., Olkhov‐Mitsel, E., Kron, K. J., Pethe, V. V., Lehman, M., Jovanovic, L., Fleshner, N. E., van der Kwast, T., Nelson, C. C., et al. (2014) · PubMed Central · Cited by 19
Analysis of somatostatin receptors and somatostatin promoter methylation in human gastric cancer
Shi, X., Xiao, L., Chen, L., & Wang, C. (2013) · Oncology Letters · doi:10.3892/ol.2013.1614 · Cited by 19
Zhang, M., Lv, X., Jiang, Y., Li, G., & Qiao, Q. (2019) · Experimental and Therapeutic Medicine · doi:10.3892/etm.2019.7807 · Cited by 18
Chen, W., Ding, R., Tang, J., Li, H., Chen, C., Zhang, Y., Zhang, Q., & Zhu, X. (2020) · Cancer Management and Research · doi:10.2147/cmar.s236374 · Cited by 16
Reply to ‘H-STS, L-STS and KRJ-I are not authentic GEPNET cell lines’
Alvarez, M. J., Yan, P., Alpaugh, M. L., Bowden, M., Sicińska, E., Zhou, C. W., Karan, C., Realubit, R. B., Mundi, P. S., Grunn, A., et al. (2019) · Nature Genetics · doi:10.1038/s41588-019-0509-5 · Cited by 15
Stafford, N., Condon, L. T., Rogers, M. J. C., Macdonald, A. W., & Atkin, S. L. (2003) · Clinical Otolaryngology · doi:10.1046/j.1365-2273.2003.00711.x · Cited by 14
Werner, C., Dirsch, O., Dahmen, U., Grimm, M., Schulz, S., & Lupp, A. (2020) · Translational Oncology · doi:10.1016/j.tranon.2020.100801 · Cited by 14
Patai, Á. V., Barták, B. K., Péterfia, B. F., Micsík, T., Horváth, R., Sumánszki, C., Péter, Z., Patai, Á., Valcz, G., Kalmár, A., et al. (2016) · Pathology & Oncology Research · doi:10.1007/s12253-016-0154-6 · Cited by 13
Wu, J., Gu, Y., Xiao, Y., Xia, C., Li, H., Kang, Y., Sun, J., Shao, Z., Lin, Z., & Zhao, X. (2019) · Frontiers in Genetics · doi:10.3389/fgene.2018.00711 · Cited by 13
H-STS, L-STS and KRJ-I are not authentic GEPNET cell lines
Hofving, T., Karlsson, J. W., Nilsson, O., & Nilsson, J. A. (2019) · Nature Genetics · doi:10.1038/s41588-019-0490-z · Cited by 5
Wajchenberg (2000) · doi:10.1002/(sici)1097-0142(20000215)88:4
Flagged first, then by citations
4 of the 114 references couldn’t be matched to a known paper.
Cited by
Sorted by citations
Popa, O., Tăban, S. M., Pantea, Ș., Plopeanu, A., Barna, R. A., Cornianu, M., Pascu, A. A., & Dema, A. L. C. (2021) · Experimental and Therapeutic Medicine · doi:10.3892/etm.2021.10613 · Cited by 85
Shi, M., Jakobsson, V., Greifenstein, L., Khong, P.-L., Chen, X., Baum, R. P., & Zhang, J. (2022) · Frontiers in Medicine · doi:10.3389/fmed.2022.1034315 · Cited by 68
Role of Somatostatin Signalling in Neuroendocrine Tumours
Rogoza, O., Megnis, K., Kudrjavceva, M., Geriņa-Bērziņa, A., & Rovīte, V. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23031447 · Cited by 62
Peptide Receptor Radionuclide Therapy
Hofland, J., Brabander, T., Verburg, F. A., Feelders, R. A., & de Herder, W. W. (2022) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgac574 · Cited by 50
Peptide Radioligands in Cancer Theranostics: Agonists and Antagonists
Nock, B. A., Kanellopoulos, P., Joosten, L., Mansi, R., & Μάινα, Θ. (2023) · Pharmaceuticals · doi:10.3390/ph16050674 · Cited by 46
Neuroendocrine tumor theranostics
Ichikawa, Y., Kobayashi, N., Takano, S., Kato, I., Endo, K., & Inoue, T. (2022) · Cancer Science · doi:10.1111/cas.15327 · Cited by 45
Structure and Function of Somatostatin and Its Receptors in Endocrinology
Zhang, B., Li, X., & Wu, Z. B. (2024) · Endocrine Reviews · doi:10.1210/endrev/bnae022 · Cited by 42
Neuropeptides in Cancer: Friend and Foe?
Wu, Y., Berisha, A., & Borniger, J. C. (2022) · Advanced Biology · doi:10.1002/adbi.202200111 · Cited by 30
Fonti, R., Panico, M., Pellegrino, S., Pulcrano, A., Vastarella, L. A., Torbati, A. H. M., Giuliano, M., Palmieri, G., Placido, S. D., & Vecchio, S. D. (2022) · Journal of Nuclear Medicine · doi:10.2967/jnumed.121.262928 · Cited by 28
Watanabe, H., Fujishima, F., Komoto, I., Imamura, M., Hijioka, S., Hara, K., Yatabe, Y., Kudo, A., Masui, T., Tsuchikawa, T., et al. (2022) · Cancers · doi:10.3390/cancers14030775 · Cited by 25
Shah, R. G., Merlin, M. A., Adant, S., Zine-Eddine, F., Beauregard, J., & Shah, G. M. (2021) · Cancers · doi:10.3390/cancers13020232 · Cited by 24
Milewska-Kranc, A., Ćwikła, J. B., & Kolasińska, A. D. (2023) · Cancers · doi:10.3390/cancers16010116 · Cited by 21
Paulus, J., & Sewald, N. (2024) · Journal of Peptide Science · doi:10.1002/psc.3561 · Cited by 24
Klomp, M. J., Dalm, S. U., van Koetsveld, P. M., Dogan, F., de Jong, M., & Hofland, L. J. (2021) · Cancers · doi:10.3390/cancers13194905 · Cited by 23
Sharma, R., Earla, B., Baidoo, K. E., Zeiger, M. A., Madigan, J. P., Escorcia, F. E., & Sadowski, S. M. (2023) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-22-0798 · Cited by 20
Pancreatic Neuroendocrine Tumors: Signaling Pathways and Epigenetic Regulation
Saleh, Z., Moccia, M. C., Ladd, Z., Joneja, U., Li, Y., Spitz, F. J., Hong, Y. K., & Gao, T. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25021331 · Cited by 18
Somatostatin and Its Receptor System in Colorectal Cancer
Kasprzak, A. (2021) · Biomedicines · doi:10.3390/biomedicines9111743 · Cited by 19
Peptide Conjugated Boron Neutron Capture Therapy for Enhanced Tumor Targeting
Jyothi, V. G. S. S., & Kommineni, N. (2024) · Nanotheranostics · doi:10.7150/ntno.95251 · Cited by 17
Ullrich, M., Richter, S., Liers, J., Drukewitz, S., Friedemann, M., Kotzerke, J., Ziegler, C. G., Nölting, S., Kopka, K., & Pietzsch, J. (2022) · Theranostics · doi:10.7150/thno.77918 · Cited by 16
Richter, S., Steenblock, C., Fischer, A., Lemm, S., Ziegler, C. G., Bechmann, N., Nölting, S., Pietzsch, J., & Ullrich, M. (2023) · Theranostics · doi:10.7150/thno.87345 · Cited by 16
Massironi, S., Albertelli, M., Hasballa, I., Paravani, P., Ferone, D., Faggiano, A., & Danese, S. (2025) · Cells · doi:10.3390/cells14040245 · Cited by 15
Kotzerke, J., Buesser, D., Naumann, A., Runge, R., Huebinger, L., Kliewer, A., Freudenberg, R., & Brogsitter, C. (2022) · Cancers · doi:10.3390/cancers14102513 · Cited by 15
Epigenetic Regulation in Gastroenteropancreatic Neuroendocrine Tumors
Crabtree, J. S. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.901435 · Cited by 17
Leupe, H., Cauwenbergh, M., Cleeren, F., Dekervel, J., Verslype, C., & Deroose, C. M. (2025) · Pharmaceuticals · doi:10.3390/ph18111608 · Cited by 14
Epigenetic regulation of SST2 expression in small intestinal neuroendocrine tumors
Klomp, M. J., Refardt, J. C., van Koetsveld, P. M., Campana, C., Dalm, S. U., Dogan, F., van Velthuysen, M. F., Feelders, R. A., de Herder, W. W., Hofland, J., et al. (2023) · Frontiers in Endocrinology · doi:10.3389/fendo.2023.1184436 · Cited by 12
Bokhout, L., Campeiro, J. D., & Dalm, S. U. (2025) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-025-07123-3 · Cited by 13
The State-of-the-Art Mechanisms and Antitumor Effects of Somatostatin in Colorectal Cancer: A Review
Kasprzak, A., & Geltz, A. (2024) · Biomedicines · doi:10.3390/biomedicines12030578 · Cited by 12
Applying HDACis to increase SSTR2 expression and radiolabeled DOTA-TATE uptake: from cells to mice
Klomp, M. J., van den Brink, L., van Koetsveld, P. M., de Ridder, C. M. A., Stuurman, D. C., Löwik, C. W. G. M., Hofland, L. J., & Dalm, S. U. (2023) · Life Sciences · doi:10.1016/j.lfs.2023.122173 · Cited by 9
Gastroenteropancreatic neuroendocrine tumors: Epigenetic landscape and clinical implications
McMurry, H. S., Rivero, J. D., Chen, E. Y.-S., Kardosh, A., Lopez, C. D., & Pegna, G. J. (2024) · Current Problems in Cancer · doi:10.1016/j.currproblcancer.2024.101131 · Cited by 11
Auernhammer, C. J., Zitzmann, K., Lindner, S., Ilhan, H., Bartenstein, P., Macciò, U., Orth, M., Peischer, L., Maurer, J., Spoettl, G., et al. (2025) · Neuroendocrinology · doi:10.1159/000545073 · Cited by 9
Resistance of neuroendocrine tumours to somatostatin analogs
Angelousi, A., Koumarianou, A., Chatzellis, E., & Kaltsas, G. (2023) · Expert Review of Endocrinology & Metabolism · doi:10.1080/17446651.2023.2166488 · Cited by 6
Octreotide attenuates intestinal barrier damage by maintaining basal autophagy in Caco2 cells
Liu, X., Zhou, Y., Zhang, Y., Cui, X., Yang, D., & Li, Y. (2024) · Molecular Medicine Reports · doi:10.3892/mmr.2024.13214 · Cited by 8
Lynch, S. E., Crawford, C. I., Houson, H. A., Omweri, J. M., Pukkanasut, P., Gallegos, C., Whitt, J. D., Jaskula‐Sztul, R., Lapi, S. E., & Sorace, A. G. (2025) · Scientific Reports · doi:10.1038/s41598-025-94578-x · Cited by 7
Optimisation of radioligand therapy in neuroendocrine tumours: Current and evolving evidence
Navalkissoor, S., Gnanasegaran, G., & Grossman, A. B. (2022) · Journal of Neuroendocrinology · doi:10.1111/jne.13208 · Cited by 7
Epigenetic Alteration of H3K27me3 as a Possible Oncogenic Mechanism of Central Neurocytoma
Kim, H., Lee, K.-H., Shim, Y., Kim, E. E., Kim, S., Phi, J. H., Park, C., Choi, S. H., & Park, S. (2023) · Laboratory Investigation · doi:10.1016/j.labinv.2023.100159 · Cited by 7
Mukherjee, S. B., Shanker, R. M., Madigan, J. P., & Sadowski, S. M. (2025) · Cancers · doi:10.3390/cancers17132080 · Cited by 6
Weich, A., Rogoll, D., Peschka, M. T., Weich, W., Pongracz, J. E., Brand, M., Fröhlich, M., Serfling, S. E., Rowe, S. P., Kosmala, A., et al. (2023) · Nuclear Medicine Communications · doi:10.1097/mnm.0000000000001666 · Cited by 5
Ray, S. K., & Mukherjee, S. (2022) · Current Molecular Medicine · doi:10.2174/1566524022666220511123104 · Cited by 5
Melhorn, P., Tomasich, E., Blessing, A., Brčić, L., Kogler, A., Draschl, A., Mazal, P. R., Berghoff, A. S., Raderer, M., Preusser, M., et al. (2025) · Endocrine Pathology · doi:10.1007/s12022-025-09847-2 · Cited by 4
Xiao, M., Tong, W., Xiao, X., Pu, X., & Yi, F. (2024) · Frontiers in Oncology · doi:10.3389/fonc.2024.1398673 · Cited by 3
Sharma, R., Earla, B., Baidoo, K. E., Zeiger, M. A., Madigan, J. P., Escorcia, F. E., & Sadowski, S. M. (2022) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2022.04.25.489401 · Cited by 3
Beek, E. T. T., Gerritse, S. L., & Verburg, F. A. (2025) · The Journal of Clinical Pharmacology · doi:10.1002/jcph.70128 · Cited by 2
Fischer, A., Macciò, U., Inukai, J. I., Zitzmann, K., Auernhammer, C. J., Hantel, C., Robledo, M., Völter, F., Hüllner, M. W., Grossman, A. B., et al. (2026) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-026-07897-0 · Cited by 2
Geltz, A., Seraszek‐Jaros, A., Andrzejewska, M., Pietras, P., Leśniczak-Staszak, M., Szaflarski, W., Szmeja, J., & Kasprzak, A. (2024) · Cancers · doi:10.3390/cancers16213584 · Cited by 2
Pellegrino, S., Panico, M., Bologna, R., Morra, R. P., Servetto, A., Bianco, R., Vecchio, S. D., & Fonti, R. (2025) · Biomedicines · doi:10.3390/biomedicines13061286 · Cited by 2
Madigan, J. P., Andrews, S. G., Farrell, R. B., Forsythe, S. D., Sharma, R., Ceribelli, M., Thomas, C. J., Shamsian, K. N., Lin, S., Cheng, K. C.-C., et al. (2025) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2025.09.23.677935 · Cited by 2
Jaiuea, P., Kongmuang, S., Lumyong, K., Doungta, T., & Shiratori, S. (2024) · Siriraj Medical Journal/San Sirirat · doi:10.33192/smj.v76i11.270157 · Cited by 1
Shen, Z., Zhang, X., Li, Q., & Wang, R. (2024) · Radiology Case Reports · doi:10.1016/j.radcr.2024.03.051 · Cited by 1
Meyers, M., Awada, A. H., Karfis, I., de Roodenbeke, D. '. K., Couvert, H. P. V., Hanssens, C., Hendlisz, A., & Driessens, N. (2024) · Case Reports in Oncology · doi:10.1159/000540707 · Cited by 2
Recent advances in functionalized macrocyclic polyamines for medicine applications
Chang, H., Qiao, R., & Li, C. (2024) · Chinese Chemical Letters · doi:10.1016/j.cclet.2024.110675 · Cited by 1
Prajapati, K. S., Singh, A. K., Shuaib, M., Kushwaha, P. P., Kumar, S., & Gupta, S. (2020) · annals of urologic oncology · doi:10.32948/auo.2020.12.03 · Cited by 1
Medikamentöse Systemtherapie bei Neuroendokrinen Neoplasien des GastroEnteropankreatischen Systems
Auernhammer, C. J., Böck, S., Westphalen, C. B., Beyer, L., & Spitzweg, C. (2021) · Der Nuklearmediziner · doi:10.1055/a-1556-8264
Tumor Markers of Neuroendocrine Tumors and Management of Carcinoid Crisis
Hacıoğlu, A., Karaca, Z., & Keleştimur, F. (2021) · Nuclear Medicine Seminars · doi:10.4274/nts.galenos.2021.0034
Cyphetrylin effect on somatostatin receptors expression in transplantable Ca-755 mice tumor
Kiseleva, M., Borisova, L., Delektorskaya, V., Shprakh, Z., Ustinkina, S. В., & Kubasova, I. (2022) · Russian Journal of Biotherapy · doi:10.17650/1726-9784-2022-21-3-50-60
Pérez, D. J., Razo‐Hernández, R. S., & Avila-Rodriguez, M. A. (2023) · Anti-Cancer Agents in Medicinal Chemistry · doi:10.2174/1871520623666230104160635
Lobo, D. S., Brabo, E. P., & de Souza, S. A. L. (2023) · Advances in Cancer Biology - Metastasis · doi:10.1016/j.adcanc.2023.100100
Vladova, P. (2022) · Trakia Journal of Sciences · doi:10.15547/tjs.2022.04.010
Sharma, R., Earla, B., Baidoo, K. E., Zeiger, M. A., Madigan, J. P., Escorcia, F. E., & Sadowski, S. M. (2023) · doi:10.1158/1535-7163.c.6784858.v2
Apoptosis-related factors are relevant to progression of pancreatic neuroendocrine tumors
Amano, S., Hirashita, T., Kawano, Y., Nishida, H., Orimoto, H., Kawamura, M., Kawasaki, T., Masuda, T., Endo, Y., Ohta, M., et al. (2023) · World Journal of Surgical Oncology · doi:10.1186/s12957-023-03267-4
CK2 regulates somatostatin expression in pancreatic delta cells
Wrublewsky, S., Clemenz, A., Boewe, A. S., Wilden, C., Bickelmann, C., Götz, C., MacDonald, P. E., Laschke, M. W., & Ampofo, E. (2025) · Islets · doi:10.1080/19382014.2025.2515332
Fu, Y., Du, S., Nie, S., Shao, Q., Guo, W., Li, Y., & Lou, L. (2025) · Annals of Diagnostic Pathology · doi:10.1016/j.anndiagpath.2025.152560
Amano, S., Hirashita, T., Kawano, Y., Nishida, H., Orimoto, H., Kawamura, M., Kawasaki, T., Masuda, T., Endo, Y., Ohta, M., et al. (2023) · Figshare · doi:10.6084/m9.figshare.24792310
Vargas-Guzmán, V. H., Rodriguez-Quintana, E. R., Cavazos-Loya, C., & del Angel, M. T. (2025) · Revista Internacional de Salud Materno Fetal · doi:10.47784/rismf.2025.10.4.431
Däubler, C., Böttcher, C., Landwehr, L., Hartrampf, P. E., Meining, A., Werner, R. A., Zhi, Y., Kimpel, O., Kloock, S., Dischinger, U., et al. (2026) · Cancers · doi:10.3390/cancers18091368
Zhou, H., Li, C., Gu, W., Feng, Y., Li, X., Chen, D., Liu, Y., Liu, F., Cheng, Y., Xu, C., et al. (2026) · The FASEB Journal · doi:10.1096/fj.202600882r
Neuroendocrine tumours through an epigenetic lens: Emerging insights for diagnosis and treatment
Jacquot, V., Chevalier, B., Walter, T., Gibert, B., & Ouzounova, M. (2026) · Journal of Neuroendocrinology · doi:10.1111/jne.70211
Theranostics in Cancer: Integration of Diagnosis and Therapy
Ali, A., Paul, A., Ogoe, M., Khan, S., & Upadhyay, T. K. (2026) · Springer eBooks · doi:10.1007/978-981-92-0477-9_13
The metastatic spectrum in functional and non-functional NENs: mechanistic insights from multi-omics
Wang, Z., Ji, X., Wang, Z., Zheng, S., Liu, F., Lü, J., & Chang, H. (2026) · Frontiers in Endocrinology · doi:10.3389/fendo.2026.1782791
Gut microbiota as a modulator of HDAC: insights into Alzheimer’s disease treatment
Verma, E., Mishra, S., Chellammal, H. S. J., Khandige, P. S., & Gasmi, A. (2026) · Pharmacological Reports · doi:10.1007/s43440-026-00897-9 · Cited by 1
Metadata
- Authors
- Klomp, M. J., Dalm, S. U., de Jong, M., Feelders, R. A., Hofland, J., & Hofland, L. J.
- Affiliations
- Erasmus MC (NL)
- Corresponding author
- Hofland, J.
- Hofland, L.J.
- Venue
- Reviews in Endocrine and Metabolic Disorders
- Published
- 2020-10-21
- Volume
- 22
- Issue
- 3
- Pages
- 495-510
- ISSN
- 1389-9155 (ISSN-L)
- 1573-2606
- PMC
- PMC8346415
- OpenAlex
- W3094440986
- Cited by
- 69
- References
- 114
- Citations by year
- 2026: 7 · 2025: 13 · 2024: 13 · 2023: 14 · 2022: 15 · 2021: 6 · 2020: 1
- FWCI
- 1.32
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Locations
- Reviews in Endocrine and Metabolic Disorders (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- EUR Research Repository (Erasmus University Rotterdam) (submittedVersion, other-oa)
- Funders
- Mrace Grant 2017
- Topics
- Health Sciences › Medicine › Oncology › Neuroendocrine Tumor Research Advances
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neuropeptides and Animal Physiology
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Epigenetics and DNA Methylation
- Keywords
- somatostatin, somatostatin receptors, somatostatin receptor 2, neuroendocrine tumors, epigenetic regulation, gene expression regulation, somatostatin analogues, radiolabeled somatostatin analogues, cancer
- MeSH terms
- Humans, Somatostatin, Receptors, Somatostatin, Neuroendocrine Tumors, Epigenesis, Genetic
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
